Sam Ladjevardi

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

A systematic analysis of the impact of data variation on AI-based histopathological grading of prostate cancer.

A systematic analysis of the impact of data variation on AI-based histopathological grading of prostate cancer.

Journal: Medical image analysis

Published: May 08, 2025

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.

Journal: Molecular therapy. Oncology

Published: October 02, 2024

Robust, credible, and interpretable AI-based histopathological prostate cancer grading.

Robust, credible, and interpretable AI-based histopathological prostate cancer grading.

Journal: medRxiv : the preprint server for health sciences

Published: July 23, 2024

Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study.

Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study.

Journal: European journal of clinical investigation

Published: December 28, 2023

P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.

P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.

Journal: The Prostate

Published: December 20, 2022

Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade.

Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour grade.

Journal: Cytopathology : official journal of the British Society for Clinical Cytology

Published: December 01, 2022

Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour.

Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour.

Journal: Cancers

Published: May 07, 2021

Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors.

Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors.

Journal: Acta radiologica open

Published: November 24, 2020

Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [11C]-Acetate PET/CT.

Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [11C]-Acetate PET/CT.

Journal: International journal of medical sciences

Published: October 22, 2019

Changes of arterial pressure following relief of obstruction in adults with hydronephrosis.

Changes of arterial pressure following relief of obstruction in adults with hydronephrosis.

Journal: Upsala journal of medical sciences

Published: October 09, 2018

Periprocedural outcome after laparoscopic partial nephrectomy versus radiofrequency ablation for T1 renal tumors: a modified R.E.N.A.L nephrometry score adjusted comparison.

Periprocedural outcome after laparoscopic partial nephrectomy versus radiofrequency ablation for T1 renal tumors: a modified R.E.N.A.L nephrometry score adjusted comparison.

Journal: Acta radiologica (Stockholm, Sweden : 1987)

Published: June 19, 2018

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.

Journal: The Journal of urology

Published: July 01, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026